<!DOCTYPE html><html lang="en-gb" >

<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  
  
  
  <meta name="generator" content="Wowchemy 5.0.0-beta.0 for Hugo">
  

  

  
  

  
  
  
  
  
    
    
    
  
  

  <meta name="author" content="Stef van Buuren">

  
  
  
    
  
  <meta name="description" content="Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear. Design and Participants: A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2). d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg. d) or conventional (0.06 mg/kg. d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed. Results: Compared with GH&#43;Pl, GH&#43;Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean &#43;/- sd, 9.5 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 &#43;/- 4.9 vs. 6.8 &#43;/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P &lt; 0.001), adult height gain on GH&#43;Ox 0.06 was not significantly different from that on GH&#43;Pl (8.3 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.3). Breast development was slower on GH&#43;Ox (GH&#43;Ox 0.03, P = 0.02; GH&#43;Ox 0.06, P = 0.05), and more girls reported virilization on GH&#43;Ox 0.06 than on GH&#43;Pl (P &lt; 0.001). Conclusions: In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg. d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg. d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development. JID: 0375362; 0 (Androgens); 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 53-39-4 (Oxandrolone); 2010/01/08 [aheadofprint]; ppublish">

  
  <link rel="alternate" hreflang="en-gb" href="https://stefvanbuuren.name/publication/menke-2010/">

  







  




  
  
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  

  
  
  
  <meta name="theme-color" content="#2962ff">
  

  
  

  
  
  
  
    
    
      <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.9.0/css/academicons.min.css" integrity="sha512-W4yqoT1+8NLkinBLBZko+dFB2ZbHsYLDdr50VElllRcNt2Q4/GSs6u71UHKxB7S6JEMCp5Ve4xjh3eGQl/HRvg==" crossorigin="anonymous">
    
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.14.0/css/all.min.css" integrity="sha256-FMvZuGapsJLjouA6k7Eo2lusoAX9i0ShlWFG6qt7SLc=" crossorigin="anonymous">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.css" integrity="sha256-Vzbj7sDDS/woiFS3uNKo8eIuni59rjyNGtXfstRzStA=" crossorigin="anonymous">

    
    
    
      
    
    
      
      
        
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/github.min.css" crossorigin="anonymous" title="hl-light">
          <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/styles/dracula.min.css" crossorigin="anonymous" title="hl-dark" disabled>
        
      
    

    

    

    
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
    
      

      
      

      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/lazysizes/5.2.2/lazysizes.min.js" integrity="sha512-TmDwFLhg3UA4ZG0Eb4MIyT1O1Mb+Oww5kFG0uHqXsdbyZz9DcvYQhKpGgNkamAI6h2lGGZq2X8ftOJvF/XjTUg==" crossorigin="anonymous" async></script>
      
    
      

      
      

      
    
      

      
      

      
    
      

      
      
        
      

      
    
      

      
      

      
    
      

      
      

      
    

  

  
  
  
    
      
      
      <link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Montserrat:400,700%7CRoboto:400,400italic,700%7CRoboto+Mono&display=swap">
    
  

  
  
  
  
  <link rel="stylesheet" href="/css/wowchemy.css">

  




  

  


  
  

  

  <link rel="manifest" href="/index.webmanifest">
  <link rel="icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_32x32_fill_lanczos_center_2.png">
  <link rel="apple-touch-icon" type="image/png" href="/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_2.png">

  <link rel="canonical" href="https://stefvanbuuren.name/publication/menke-2010/">

  
  
  
  
  
  
  
    
    
  
  
  <meta property="twitter:card" content="summary">
  
  <meta property="og:site_name" content="Stef van Buuren">
  <meta property="og:url" content="https://stefvanbuuren.name/publication/menke-2010/">
  <meta property="og:title" content="Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome | Stef van Buuren">
  <meta property="og:description" content="Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear. Design and Participants: A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2). d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg. d) or conventional (0.06 mg/kg. d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed. Results: Compared with GH&#43;Pl, GH&#43;Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean &#43;/- sd, 9.5 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 &#43;/- 4.9 vs. 6.8 &#43;/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P &lt; 0.001), adult height gain on GH&#43;Ox 0.06 was not significantly different from that on GH&#43;Pl (8.3 &#43;/- 4.7 vs. 7.2 &#43;/- 4.0 cm, P = 0.3). Breast development was slower on GH&#43;Ox (GH&#43;Ox 0.03, P = 0.02; GH&#43;Ox 0.06, P = 0.05), and more girls reported virilization on GH&#43;Ox 0.06 than on GH&#43;Pl (P &lt; 0.001). Conclusions: In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg. d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg. d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development. JID: 0375362; 0 (Androgens); 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 53-39-4 (Oxandrolone); 2010/01/08 [aheadofprint]; ppublish"><meta property="og:image" content="https://stefvanbuuren.name/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.png">
  <meta property="twitter:image" content="https://stefvanbuuren.name/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_512x512_fill_lanczos_center_2.png"><meta property="og:locale" content="en-gb">
  
    
      <meta property="article:published_time" content="2020-11-06T08:11:50&#43;00:00">
    
    <meta property="article:modified_time" content="2020-11-06T09:11:50&#43;01:00">
  

  


    









<script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "Article",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://stefvanbuuren.name/publication/menke-2010/"
  },
  "headline": "Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome",
  
  "datePublished": "2020-11-06T08:11:50Z",
  "dateModified": "2020-11-06T09:11:50+01:00",
  
  "author": {
    "@type": "Person",
    "name": "L. A. Menke"
  },
  
  "publisher": {
    "@type": "Organization",
    "name": "Stef van Buuren",
    "logo": {
      "@type": "ImageObject",
      "url": "https://stefvanbuuren.name/images/icon_hu0b7a4cb9992c9ac0e91bd28ffd38dd00_9727_192x192_fill_lanczos_center_2.png"
    }
  },
  "description": "Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear. Design and Participants: A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2). d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg. d) or conventional (0.06 mg/kg. d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed. Results: Compared with GH+Pl, GH+Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean +/- sd, 9.5 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 +/- 4.9 vs. 6.8 +/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P \u003c 0.001), adult height gain on GH+Ox 0.06 was not significantly different from that on GH+Pl (8.3 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.3). Breast development was slower on GH+Ox (GH+Ox 0.03, P = 0.02; GH+Ox 0.06, P = 0.05), and more girls reported virilization on GH+Ox 0.06 than on GH+Pl (P \u003c 0.001). Conclusions: In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg. d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg. d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development. JID: 0375362; 0 (Androgens); 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 53-39-4 (Oxandrolone); 2010/01/08 [aheadofprint]; ppublish"
}
</script>

  

  


  


  





  <title>Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome | Stef van Buuren</title>

</head>


<body id="top" data-spy="scroll" data-offset="70" data-target="#TableOfContents" class="page-wrapper  ">

  
  
  
  
  
  <script src="/js/wowchemy-init.js"></script>

  <aside class="search-results" id="search">
  <div class="container">
    <section class="search-header">

      <div class="row no-gutters justify-content-between mb-3">
        <div class="col-6">
          <h1>Search</h1>
        </div>
        <div class="col-6 col-search-close">
          <a class="js-search" href="#"><i class="fas fa-times-circle text-muted" aria-hidden="true"></i></a>
        </div>
      </div>

      <div id="search-box">
        
        <input name="q" id="search-query" placeholder="Search..." autocapitalize="off"
        autocomplete="off" autocorrect="off" spellcheck="false" type="search" class="form-control">
        
      </div>

    </section>
    <section class="section-search-results">

      <div id="search-hits">
        
      </div>

    </section>
  </div>
</aside>


  <div class="page-header">
    












<nav class="navbar navbar-expand-lg navbar-light compensate-for-scrollbar" id="navbar-main">
  <div class="container">

    
    <div class="d-none d-lg-inline-flex">
      <a class="navbar-brand" href="/">Stef van Buuren</a>
    </div>
    

    
    <button type="button" class="navbar-toggler" data-toggle="collapse"
            data-target="#navbar-content" aria-controls="navbar" aria-expanded="false" aria-label="Toggle navigation">
    <span><i class="fas fa-bars"></i></span>
    </button>
    

    
    <div class="navbar-brand-mobile-wrapper d-inline-flex d-lg-none">
      <a class="navbar-brand" href="/">Stef van Buuren</a>
    </div>
    

    
    
    <div class="navbar-collapse main-menu-item collapse justify-content-start" id="navbar-content">

      
      <ul class="navbar-nav d-md-inline-flex">
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#about"><span>Home</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
        

        <li class="nav-item">
          <a class="nav-link " href="/publication/"><span>Publications</span></a>
        </li>

        
        

        

        
        
        
          
        

        

        
        
        
        

        
          
            
            
          
          
            
            
            
              
            
            
          
        

        <li class="nav-item">
          <a class="nav-link " href="/#contact"><span>Contact</span></a>
        </li>

        
        

      

        
      </ul>
    </div>

    <ul class="nav-icons navbar-nav flex-row ml-auto d-flex pl-md-2">
      
      
      <li class="nav-item">
        <a class="nav-link js-search" href="#" aria-label="Search"><i class="fas fa-search" aria-hidden="true"></i></a>
      </li>
      

      
      
      <li class="nav-item dropdown theme-dropdown">
        <a href="#" class="nav-link" data-toggle="dropdown" aria-haspopup="true" aria-label="Display preferences">
          <i class="fas fa-moon" aria-hidden="true"></i>
        </a>
        <div class="dropdown-menu">
          <a href="#" class="dropdown-item js-set-theme-light">
            <span>Light</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-dark">
            <span>Dark</span>
          </a>
          <a href="#" class="dropdown-item js-set-theme-auto">
            <span>Automatic</span>
          </a>
        </div>
      </li>
      

      

    </ul>

  </div>
</nav>


  </div>

  <div class="page-body">
    








<div class="pub">

  












  

  
  
  
<div class="article-container pt-3">
  <h1>Efficacy and safety of oxandrolone in growth hormone-treated girls with turner syndrome</h1>

  

  
    


<div class="article-metadata">

  
  
  
  
  <div>
    

  
  <span ><a href="/author/l.-a.-menke/">L. A. Menke</a></span>, <span ><a href="/author/t.-c.-sas/">T. C. Sas</a></span>, <span ><a href="/author/s.-m.p.f.-de-muinck-keizer-schrama/">S. M.P.F. de Muinck Keizer-Schrama</a></span>, <span ><a href="/author/g.-r.-zandwijken/">G. R. Zandwijken</a></span>, <span ><a href="/author/m.-a.-de-ridder/">M. A. de Ridder</a></span>, <span ><a href="/author/r.-j.-odink/">R. J. Odink</a></span>, <span ><a href="/author/m.-jansen/">M. Jansen</a></span>, <span ><a href="/author/h.-a.-delemarre-van-de-waal/">H. A. Delemarre-van de Waal</a></span>, <span ><a href="/author/w.-h.-stokvis-brantsma/">W. H. Stokvis-Brantsma</a></span>, <span ><a href="/author/j.-j.-waelkens/">J. J. Waelkens</a></span>, <span ><a href="/author/c.-westerlaken/">C. Westerlaken</a></span>, <span ><a href="/author/h.-m.-reeser/">H. M. Reeser</a></span>, <span ><a href="/author/a.-s.-van-trotsenburg/">A. S. van Trotsenburg</a></span>, <span ><a href="/author/e.-f.-gevers/">E. F. Gevers</a></span>, <span class="author-highlighted"><a href="/author/stef-van-buuren/">Stef van Buuren</a></span>, <span ><a href="/author/p.-h.-dejonckere/">P. H. Dejonckere</a></span>, <span ><a href="/author/ac-hokken-koelega/">AC Hokken-Koelega</a></span>, <span ><a href="/author/b.-j.-otten/">B. J. Otten</a></span>, <span ><a href="/author/j.-m.-wit/">J. M. Wit</a></span>
  </div>
  
  

  
  <span class="article-date">
    
    
      
    
    January 2010
  </span>
  

  

  

  
  
  
  
  

  
  

</div>

    











  



<div class="btn-links mb-3">
  
  








  
    
  



<a class="btn btn-outline-primary my-1 mr-1" href="/publications/2010%20Efficacy%20Oxandrolone%20-%20JECM.pdf" target="_blank" rel="noopener">
  PDF
</a>



<button type="button" class="btn btn-outline-primary my-1 mr-1 js-cite-modal"
        data-filename="/publication/menke-2010/cite.bib">
  Cite
</button>















</div>


  
</div>



  <div class="article-container">

    
    <h3>Abstract</h3>
    <p class="pub-abstract">Context and Objective: GH therapy increases growth and adult height in Turner syndrome (TS). The benefit to risk ratio of adding the weak androgen oxandrolone (Ox) to GH is unclear. Design and Participants: A randomized, placebo-controlled, double-blind, dose-response study was performed in 10 centers in The Netherlands. One hundred thirty-three patients with TS were included in age group 1 (2-7.99 yr), 2 (8-11.99 yr), or 3 (12-15.99 yr). Patients were treated with GH (1.33 mg/m(2). d) from baseline, combined with placebo (Pl) or Ox in low (0.03 mg/kg. d) or conventional (0.06 mg/kg. d) dose from the age of 8 yr and estrogens from the age of 12 yr. Adult height gain (adult height minus predicted adult height) and safety parameters were systematically assessed. Results: Compared with GH+Pl, GH+Ox 0.03 increased adult height gain in the intention-to-treat analysis (mean +/- sd, 9.5 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.02) and per-protocol analysis (9.8 +/- 4.9 vs. 6.8 +/- 4.4 cm, P = 0.02). Partly due to accelerated bone maturation (P &lt; 0.001), adult height gain on GH+Ox 0.06 was not significantly different from that on GH+Pl (8.3 +/- 4.7 vs. 7.2 +/- 4.0 cm, P = 0.3). Breast development was slower on GH+Ox (GH+Ox 0.03, P = 0.02; GH+Ox 0.06, P = 0.05), and more girls reported virilization on GH+Ox 0.06 than on GH+Pl (P &lt; 0.001). Conclusions: In GH-treated girls with TS, we discourage the use of the conventional Ox dosage (0.06 mg/kg. d) because of its low benefit to risk ratio. The addition of Ox 0.03 mg/kg. d modestly increases adult height gain and has a fairly good safety profile, except for some deceleration of breast development. JID: 0375362; 0 (Androgens); 0 (Recombinant Proteins); 12629-01-5 (Human Growth Hormone); 53-39-4 (Oxandrolone); 2010/01/08 [aheadofprint]; ppublish</p>
    

    
    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Type</div>
          <div class="col-12 col-md-9">
            <a href="/publication/#2">
              Journal article
            </a>
          </div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    
    <div class="row">
      <div class="col-md-1"></div>
      <div class="col-md-10">
        <div class="row">
          <div class="col-12 col-md-3 pub-row-heading">Publication</div>
          <div class="col-12 col-md-9"><em>J. Clin. Endocrinol. Metab.</em></div>
        </div>
      </div>
      <div class="col-md-1"></div>
    </div>
    <div class="d-md-none space-below"></div>
    

    <div class="space-below"></div>

    <div class="article-style"></div>

    




<div class="article-tags">
  
  <a class="badge badge-light" href="/tag/adolescent/">Adolescent</a>
  
  <a class="badge badge-light" href="/tag/androgens/">Androgens/</a>
  
  <a class="badge badge-light" href="/tag/blood-pressure/drug-effects/">Blood Pressure/drug effects</a>
  
  <a class="badge badge-light" href="/tag/body-height/drug-effects/">Body Height/drug effects</a>
  
  <a class="badge badge-light" href="/tag/dose-response-relationship/">Dose-Response Relationship</a>
  
  <a class="badge badge-light" href="/tag/double-blind-method/">Double-Blind Method</a>
  
  <a class="badge badge-light" href="/tag/combination/adverse-effects/">Combination/adverse effects</a>
  
  <a class="badge badge-light" href="/tag/human-growth-hormone/therapeutic-use/">Human Growth Hormone/therapeutic use</a>
  
  <a class="badge badge-light" href="/tag/oxandrolone/-administration-dosage/adverse-effects/">Oxandrolone/- administration &amp; dosage/adverse effects</a>
  
  <a class="badge badge-light" href="/tag/puberty/drug-effects/">Puberty/drug effects</a>
  
  <a class="badge badge-light" href="/tag/recombinant-proteins/therapeutic-use/">Recombinant Proteins/therapeutic use</a>
  
  <a class="badge badge-light" href="/tag/turner-syndrome/drug-therapy/">Turner Syndrome/drug therapy;</a>
  
  <a class="badge badge-light" href="/tag/virilism/chemically-induced/">Virilism/chemically induced</a>
  
</div>



<div class="share-box" aria-hidden="true">
  <ul class="share">
    
      
      
      
        
      
      
      
      <li>
        <a href="https://twitter.com/intent/tweet?url=https://stefvanbuuren.name/publication/menke-2010/&amp;text=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome" target="_blank" rel="noopener" class="share-btn-twitter">
          <i class="fab fa-twitter"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.facebook.com/sharer.php?u=https://stefvanbuuren.name/publication/menke-2010/&amp;t=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome" target="_blank" rel="noopener" class="share-btn-facebook">
          <i class="fab fa-facebook"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="mailto:?subject=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome&amp;body=https://stefvanbuuren.name/publication/menke-2010/" target="_blank" rel="noopener" class="share-btn-email">
          <i class="fas fa-envelope"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://www.linkedin.com/shareArticle?url=https://stefvanbuuren.name/publication/menke-2010/&amp;title=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome" target="_blank" rel="noopener" class="share-btn-linkedin">
          <i class="fab fa-linkedin-in"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="whatsapp://send?text=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome%20https://stefvanbuuren.name/publication/menke-2010/" target="_blank" rel="noopener" class="share-btn-whatsapp">
          <i class="fab fa-whatsapp"></i>
        </a>
      </li>
    
      
      
      
        
      
      
      
      <li>
        <a href="https://service.weibo.com/share/share.php?url=https://stefvanbuuren.name/publication/menke-2010/&amp;title=Efficacy%20and%20safety%20of%20oxandrolone%20in%20growth%20hormone-treated%20girls%20with%20turner%20syndrome" target="_blank" rel="noopener" class="share-btn-weibo">
          <i class="fab fa-weibo"></i>
        </a>
      </li>
    
  </ul>
</div>











  
  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    




  
    



  
  
  
    
  
  
  
  <div class="media author-card content-widget-hr">
    
      
      <a href="https://stefvanbuuren.name/"><img class="avatar mr-3 avatar-circle" src="/author/stef-van-buuren/avatar_hu0cbacb29b3aa92495b9fd08c3aa39555_68313_270x270_fill_q90_lanczos_center.jpg" alt="Stef van Buuren"></a>
    

    <div class="media-body">
      <h5 class="card-title"><a href="https://stefvanbuuren.name/">Stef van Buuren</a></h5>
      
      <p class="card-text">My research interests include data science, missing data, child growth and development, and measurement.</p>
      <ul class="network-icon" aria-hidden="true">
  
    
    
    
      
    
    
    
    
    
    <li>
      <a href="mailto:s.vanbuuren@uu.nl" >
        <i class="fas fa-envelope"></i>
      </a>
    </li>
  
    
    
    
    
    
    
    
      
    
    <li>
      <a href="https://scholar.google.nl/citations?user=_3y5C0UAAAAJ" target="_blank" rel="noopener">
        <i class="ai ai-google-scholar"></i>
      </a>
    </li>
  
    
    
    
      
    
    
    
    
    
      
    
    <li>
      <a href="https://github.com/stefvanbuuren" target="_blank" rel="noopener">
        <i class="fab fa-github"></i>
      </a>
    </li>
  
</ul>

    </div>
  </div>


  
    




  
    




  
    




  
    




  














  
  
  <div class="article-widget content-widget-hr">
    <h3>Related</h3>
    <ul>
      
      <li><a href="/publication/geraedts-2011/">Association between head circumference and body size</a></li>
      
      <li><a href="/publication/vanbuuren-2009-a/">Estimating regional centile curves from mixed data sources and countries</a></li>
      
      <li><a href="/publication/stocks-2011/">Body size and growth in 0- to 4-year-old children and the relation to body size in primary school age</a></li>
      
      <li><a href="/publication/heymans-2010/">The prognosis of chronic low back pain is determined by changes in pain and disability in the initial period</a></li>
      
      <li><a href="/publication/hermanussen-2010/">Growth variation, final height and secular trend. Proceedings of the 17th Aschauer Soiree, 7th November 2009</a></li>
      
    </ul>
  </div>
  





  </div>
</div>
  </div>

  <div class="page-footer">
    
    
    <div class="container">
      <footer class="site-footer">
  

  <p class="powered-by">
    © 2020
  </p>

  
  






  <p class="powered-by">
    
    
    
    Published with
    <a href="https://wowchemy.com" target="_blank" rel="noopener">Wowchemy</a>  —
    the free, <a href="https://github.com/wowchemy/wowchemy-hugo-modules" target="_blank" rel="noopener">
    open source</a> website builder that empowers creators.
    
  </p>
</footer>

    </div>
    
  </div>

  
<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <h5 class="modal-title">Cite</h5>
        <button type="button" class="close" data-dismiss="modal" aria-label="Close">
          <span aria-hidden="true">&times;</span>
        </button>
      </div>
      <div class="modal-body">
        <pre><code class="tex hljs"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-outline-primary my-1 js-copy-cite" href="#" target="_blank">
          <i class="fas fa-copy"></i> Copy
        </a>
        <a class="btn btn-outline-primary my-1 js-download-cite" href="#" target="_blank">
          <i class="fas fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

      

    
    
    
      <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.5.1/jquery.min.js" integrity="sha256-9/aliU8dGd2tb6OSsuzixeV4y/faTqgFtohetphbbj0=" crossorigin="anonymous"></script>

      
      
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.4/imagesloaded.pkgd.min.js" integrity="sha256-lqvxZrPLtfffUl2G/e7szqSvPBILGbwmsGE1MKlOi0Q=" crossorigin="anonymous"></script>
        <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.6/isotope.pkgd.min.js" integrity="sha256-CBrpuqrMhXwcLLUd5tvQ4euBHCdh7wGlDfNz8vbu/iI=" crossorigin="anonymous"></script>
      

      <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.5.7/jquery.fancybox.min.js" integrity="sha256-yt2kYMy0w8AbtF89WXb2P1rfjcP/HTHLT7097U8Y5b8=" crossorigin="anonymous"></script>
      <script src="https://cdnjs.cloudflare.com/ajax/libs/instant.page/5.1.0/instantpage.min.js" integrity="sha512-1+qUtKoh9XZW7j+6LhRMAyOrgSQKenQ4mluTR+cvxXjP1Z54RxZuzstR/H9kgPXQsVB8IW7DMDFUJpzLjvhGSQ==" crossorigin="anonymous"></script>

      

      
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/highlight.min.js" integrity="sha512-TDKKr+IvoqZnPzc3l35hdjpHD0m+b2EC2SrLEgKDRWpxf2rFCxemkgvJ5kfU48ip+Y+m2XVKyOCD85ybtlZDmw==" crossorigin="anonymous"></script>
        
        <script src="https://cdnjs.cloudflare.com/ajax/libs/highlight.js/10.2.0/languages/r.min.js"></script>
        
      

    

    
    

    
    
    <script>const code_highlighting = true;</script>
    

    
    
    
    
    
    
    <script>
      const search_config = {"indexURI":"/index.json","minLength":1,"threshold":0.3};
      const i18n = {"no_results":"No results found","placeholder":"Search...","results":"results found"};
      const content_type = {
        'post': "Posts",
        'project': "Projects",
        'publication' : "Publications",
        'talk' : "Talks",
        'slides' : "Slides"
        };
    </script>
    

    
    

    
    
    <script id="search-hit-fuse-template" type="text/x-template">
      <div class="search-hit" id="summary-{{key}}">
      <div class="search-hit-content">
        <div class="search-hit-name">
          <a href="{{relpermalink}}">{{title}}</a>
          <div class="article-metadata search-hit-type">{{type}}</div>
          <p class="search-hit-description">{{snippet}}</p>
        </div>
      </div>
      </div>
    </script>
    

    
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/3.2.1/fuse.min.js" integrity="sha256-VzgmKYmhsGNNN4Ph1kMW+BjoYJM2jV5i4IlFoeZA9XI=" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/jquery.mark.min.js" integrity="sha256-4HLtjeVgH0eIB3aZ9mLYF6E8oU5chNdjU6p6rrXpl9U=" crossorigin="anonymous"></script>
    

    
    

    
    
    

    
    

    
    

    
    
    
    
    
    
    
    
    
      
    
    
    
    
    <script src="/js/wowchemy.min.59419d2c9809de125013c581da371866.js"></script>

    






</body>
</html>
